11.17
Precedente Chiudi:
$10.75
Aprire:
$10.75
Volume 24 ore:
1.14M
Relative Volume:
0.69
Capitalizzazione di mercato:
$1.79B
Reddito:
$394.50M
Utile/perdita netta:
$-2.63M
Rapporto P/E:
-558.50
EPS:
-0.02
Flusso di cassa netto:
$70.29M
1 W Prestazione:
+17.21%
1M Prestazione:
+0.72%
6M Prestazione:
-21.61%
1 anno Prestazione:
-10.28%
Certara Inc Stock (CERT) Company Profile
Nome
Certara Inc
Settore
Industria
Telefono
(415) 237-8272
Indirizzo
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Confronta CERT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CERT
Certara Inc
|
11.17 | 1.68B | 394.50M | -2.63M | 70.29M | -0.02 |
![]()
VEEV
Veeva Systems Inc
|
279.18 | 45.26B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
69.63 | 10.57B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
64.02 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
89.27 | 8.00B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
35.35 | 6.01B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
2025-05-08 | Aggiornamento | Barclays | Equal Weight → Overweight |
2025-02-27 | Iniziato | TD Cowen | Buy |
2024-09-27 | Aggiornamento | UBS | Neutral → Buy |
2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2024-04-04 | Iniziato | JMP Securities | Mkt Perform |
2024-02-26 | Iniziato | Leerink Partners | Market Perform |
2023-12-07 | Iniziato | UBS | Neutral |
2023-12-05 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2023-08-22 | Downgrade | Jefferies | Buy → Hold |
2023-08-10 | Downgrade | William Blair | Outperform → Mkt Perform |
2023-04-12 | Iniziato | Stephens | Overweight |
2023-04-03 | Downgrade | Barclays | Overweight → Equal Weight |
2022-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
2022-09-08 | Iniziato | Berenberg | Buy |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-07-01 | Iniziato | Piper Sandler | Overweight |
2022-01-11 | Aggiornamento | Jefferies | Hold → Buy |
2021-08-05 | Ripresa | Credit Suisse | Neutral |
2021-07-23 | Iniziato | Robert W. Baird | Outperform |
2021-03-03 | Iniziato | Barclays | Overweight |
2021-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
2021-01-05 | Iniziato | BofA Securities | Buy |
2021-01-05 | Iniziato | Credit Suisse | Neutral |
2021-01-05 | Iniziato | Jefferies | Hold |
2021-01-05 | Iniziato | William Blair | Outperform |
Mostra tutto
Certara Inc Borsa (CERT) Ultime notizie
Certara (CERT) Is Up 9.0% After Simcyp Simulator Wins EMA Qualification and Q2 Sales Rise—Has the Bull Case Changed? - simplywall.st
Certara Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Certara, Inc. Reports Strong Q2 2025 Earnings Growth - TipRanks
Certara, Inc. Reports Strong Q2 2025 Growth - TipRanks
Here's Why It's Unlikely That Certara, Inc.'s (NASDAQ:CERT) CEO Will See A Pay Rise This Year - 富途牛牛
Can Traders Expect Breakout From Certara Inc. This WeekLow Capital High Return Stock Plans Reviewed - beatles.ru
Certara signals full year 8–10% revenue growth outlook as AI and QSP momentum builds - MSN
Certara, Inc. (NASDAQ:CERT) Q2 2025 Earnings Call Transcript - Insider Monkey
Certara, Inc.'s (NASDAQ:CERT) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Yahoo Finance
Certara, Inc. (CERT) Q2 Earnings Miss Estimates - MSN
Certara 2025 Q2 Earnings Narrows Losses, Reports 84.3% Reduction in Net Loss - AInvest
Navigator Holdings Ltd. shares fall 1.00% intraday after Certara, Inc. reports Q2 2025 earnings. - AInvest
Certara, Inc. (CERT): A Bull Case Theory - Insider Monkey
UBS Maintains Certara (CERT) Rating, Lowers Price Target to $15. - GuruFocus
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns By Investing.com - Investing.com South Africa
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns - Investing.com Nigeria
Certara Surges 15.58% Amid Volatile Intraday Action—What’s Fueling the Rally? - AInvest
UBS Adjusts Price Target on Certara to $15 From $17.50, Maintains Buy Rating - MarketScreener
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips - Investing.com
Certara’s Mixed Signals: Hold Rating Amidst Growth Potential and Strategic Uncertainty - TipRanks
Certara's Q2 Results and Strategic Positioning Support Buy Rating with $16 Price Target - AInvest
Certara (CERT) Q2 Revenue Jumps 12% - AOL.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara's AI-Driven Biosimulation Platform: A Catalyst for Drug Development Transformation - AInvest
Certara's Q2 2025 Earnings: Strategic Resilience in a Shifting Biosimulation Landscape - AInvest
Certara's Q2 2025 Earnings Call: Contradictory Signals on Market Potential, Demand Dynamics, and Retention Rates - AInvest
Certara Expects Full-Year Revenue Growth of 8-10% on AI, QSP Momentum - AInvest
Certara Grows In Q2 But Falls Short Of Analyst Estimates - Finimize
Certara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Press Release: Certara Reports Second Quarter 2025 Financial Results - 富途牛牛
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss By Investing.com - Investing.com South Africa
Certara Q2 adjusted EPS misses estimates - MarketScreener
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss - Investing.com UK
CERT SEC FilingsCertara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Certara Earnings: Software Revenue Surges 22% as Biosimulation Demand Drives Record Q2 Performance - Stock Titan
Visual analytics tools that track Certara Inc. performanceSwing Reversal Forecast Based on Patterns - Newser
Navigator Holdings Ltd. shares rise 1.84% intraday after Certara's Simcyp Simulator receives EMA qualification. - AInvest
The PBPK Revolution: How Certara's Simcyp Simulator is Reshaping Drug Development and Regulatory Acceptance - AInvest
Certara Simcyp Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - MarketScreener
Certara Obtains European Medicines Agency Qualification for Biosimulation Software - MarketScreener
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - The Manila Times
Certara's Simcyp® Simulator Achieves EMA Qualification for Regulatory Submissions in the EU - Quiver Quantitative
Breakthrough: Certara's Simcyp Becomes Only Software Qualified by EMA for Drug Interaction Studies - Stock Titan
Why is Certara Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
What institutional investors are buying Certara Inc. stockUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Certara Inc. expanding into Is KREF stock a good long term investment optionExceptional profit potential - Jammu Links News
What are analysts’ price targets for Certara Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is the risk reward ratio of investing in Certara Inc. stockNavigate market volatility with smart strategies - Jammu Links News
How strong is Certara Inc. company’s balance sheetFree Expert Stock Watchlist - Jammu Links News
What catalysts could drive Certara Inc. stock higher in 2025Dynamic growth stocks - Jammu Links News
Certara Inc Azioni (CERT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):